• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study

by | Apr 11, 2024 | Publications

Semin Oncol Nurs. 2024 Apr 9:151621. doi: 10.1016/j.soncn.2024.151621. Online ahead of print. ABSTRACT OBJECTIVES: Cytokine release syndrome (CRS) is a systemic inflammatory response that is commonly observed as a class effect of T-cell-redirecting therapies. This...

An IL-1beta-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma

by | Apr 11, 2024 | Publications

Nat Immunol. 2024 Apr 10. doi: 10.1038/s41590-024-01808-x. Online ahead of print. ABSTRACT Human bone marrow permanently harbors high numbers of neutrophils, and a tumor-supportive bias of these cells could significantly impact bone marrow-confined malignancies. In...

The enduring neutrophil-stroma dance of multiple myeloma

by | Apr 11, 2024 | Publications

Nat Immunol. 2024 Apr 10. doi: 10.1038/s41590-024-01810-3. Online ahead of print. NO ABSTRACT PMID:38600357 | DOI:10.1038/s41590-024-01810-3

Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis

by | Apr 11, 2024 | Publications

Transfusion. 2024 Apr 10. doi: 10.1111/trf.17829. Online ahead of print. ABSTRACT BACKGROUND: Despite recent advances in the treatment of multiple myeloma, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) remains an...

Pain Management in Multiple Myeloma Patients: A Literature Review

by | Apr 11, 2024 | Publications

Cureus. 2024 Mar 11;16(3):e55975. doi: 10.7759/cureus.55975. eCollection 2024 Mar. ABSTRACT Managing pain in cancer patients with multiple myeloma (MM) poses a considerable challenge. This review thoroughly investigates current pain management strategies,...

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

by | Apr 11, 2024 | Publications

Front Oncol. 2024 Mar 27;14:1373548. doi: 10.3389/fonc.2024.1373548. eCollection 2024. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile....
« Older Entries
Next Entries »

Recent Content

  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT